6 results on '"S. Vasikaran"'
Search Results
2. A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ß-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM)
- Author
-
Cavalier, E. Eastell, R. Jørgensen, N.R. Makris, K. Tournis, S. Vasikaran, S. Kanis, J.A. Cooper, C. Pottel, H. Morris, H.A. on behalf of the IFCC-IOF Committee for Bone Metabolism (C-BM)
- Abstract
Background: Biochemical bone turnover markers are useful tools to assess bone remodeling. C-terminal telopeptide of type I collagen (ß-CTX) has been recommended as a reference marker for bone resorption in research studies. Methods: We describe the results of a multicenter study for routine clinical laboratory assays for ß-CTX in serum and plasma. Four centers (Athens GR, Copenhagen DK, Liege BE and Sheffield UK) collected serum and plasma (EDTA) samples from 796 patients presenting to osteoporosis clinics. Specimens were analyzed in duplicate with each of the available routine clinical laboratory methods according to the manufacturers’ instructions. Passing-Bablok regressions, Bland–Altman plots, V-shape evaluation method, and Concordance correlation coefficient for ß-CTX values between serum and plasma specimens and between methods were used to determine the agreement between results. A generalized linear model was employed to identify possible variables that affected the relationship between the methods. Two pools of serum were finally prepared and sent to the four centers to be measured in 5-plicates on 5 consecutive days with the different methods. Results: We identified significant variations between methods and between centers although comparison results were generally more consistent in plasma compared to serum. We developed univariate linear regression equations to predict Roche Elecsys®, IDS-iSYS, or IDS ELISA ß-CTX results from any other assay and a multivariable model including the site of analysis, the age, and weight of the patient. The coefficients of determination (R2) increased from approximately 0.80 in the univariate model to approximately 0.90 in the multivariable one, with the site of analysis being the major contributing factor. Results observed on the pools also suggest that long-term storage could explain the difference observed with the different methods on serum. Conclusion: Our results show large within- and between-assay variation for ß-CTX measurement, particularly in serum. Stability of the analyte could be one of the explanations. More studies should be undertaken to overcome this problem. Until harmonization is achieved, we recommend measuring ß-CTX by the same assay on EDTA plasma, especially for research purposes in large pharmacological trials where samples can be stored for long periods before they are assayed. © 2021, The Author(s).
- Published
- 2021
3. A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type i procollagen (PINP): A report from the IFCC-IOF Joint Committee for Bone Metabolism
- Author
-
Cavalier, E. Eastell, R. Rye Jørgensen, N. Makris, K. Tournis, S. Vasikaran, S. Kanis, J.A. Cooper, C. Pottel, H. Morris, H.A.
- Abstract
Biochemical bone turnover markers (BTM) are useful tools to assess bone remodeling at the cellular level. N-terminal propeptide of type I procollagen (PINP) has been recommended as a reference marker for bone formation in research studies. We describe the results of a multicenter study for routine clinical laboratory assays for PINP in serum and plasma. Four centers (Athens, Greece [GR], Copenhagen, Denmark [DK], Liege, Belgium [BE] and Sheffield, United Kingdom [UK]) collected serum and plasma (EDTA) samples from 796 patients presenting to osteoporosis clinics. Specimens were analyzed in duplicate with each of the available routine clinical laboratory methods according to the manufacturers' instructions. Passing-Bablok regressions, Bland-Altman plots, V-shape evaluation method and the concordance correlation coefficient for PINP values between serum and plasma specimens and between methods were used to determine the agreement between results. A generalized linear model was employed to identify possible variables that affected the relationship between the methods. We showed that both EDTA plasma and serum were suitable for PINP determination. We observed a significant proportional bias between Orion radioimmunoassay and the automated methods for PINP (Roche Cobas and IDS iSYS), which both gave very similar results. The multivariate model did not improve the excellent correlation that was observed between the methods. Harmonization of PINP assays is possible by applying a correction factor or correctly assigning the values of the calibrators. This work will benefit from further collaboration between assays manufacturers and clinical laboratory professionals. © 2019 Walter de Gruyter GmbH, Berlin/Boston.
- Published
- 2019
4. A comprehensive fracture prevention strategy in older adults : The European union geriatric medicine society (EUGMS) statement
- Author
-
H. Blain, T. Masud, P. Dargent-Molina, F.C. Martin, E. Rosendahl, N. van der Velde, J. Bousquet, A. Benetos, C. Cooper, J.A. Kanis, J.Y. Reginster, R. Rizzoli, B. Cortet, M. Barbagallo, K. Dreinhöfer, B. Vellas, S. Maggi, T. Strandberg, M.N. Alvarez, C. Annweiler, P.-L. Bernard, N. Beswetherick, H.A. Bischoff-Ferrari, F. Bloch, J. Boddaert, M. Bonnefoy, V. Bousson, I. Bourdel-Marchasson, A. Capisizu, H. Che, J.G. Clara, B. Combe, D. Delignieres, P. Eklund, M. Emmelot-Vonk, E. Freiberger, J.-B. Gauvain, N. Goswami, N. Guldemond, Á.C. Herrero, M.-E. Joël, A.B. Jónsdóttir, G. Kemoun, I. Kiss, H. Kolk, M.L. Kowalski, Š. Krajcík, Y.G. Kutsal, F. Lauretani, J. Macijauskienė, M. Mellingsæter, J. Morel, F. Mourey, F. Nourashemi, C. Nyakas, F. Puisieux, P. Rambourg, A.G. Ramírez, K. Rapp, Y. Rolland, J. Ryg, O. Sahota, S. Snoeijs, Y. Stephan, E. Thomas, C. Todd, J. Treml, R. Adachi, D. Agnusdei, J.-J. Body, V. Breuil, O. Bruyère, P. Burckardt, J.B. Cannata-Andia, J. Carey, D.-C. Chan, L. Chapuis, T. Chevalley, M. Cohen-Solal, B. Dawson-Hughes, E.M. Dennison, J.-P. Devogelaer, P. Fardellone, J.-M. Féron, A.D. Perez, D. Felsenberg, C. Glueer, N. Harvey, M. Hiligsman, M.K. Javaid, N.R. Jörgensen, D. Kendler, M. Kraenzlin, M. Laroche, E. Legrand, W.D. Leslie, E. Lespessailles, E.M. Lewiecki, T. Nakamura, A. Papaioannou, C. Roux, S. Silverman, M.S. Henriquez, T. Thomas, S. Vasikaran, N.B. Watts, G. Weryha, Euromov (EuroMov), Université de Montpellier (UM), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Antonin Balmès, Nottingham University Hospitals, Equipe 6 : ORCHAD - Origines précoces de la santé du développement de l'enfant (CRESS - U1153), Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Guy's & St Thomas' NHS Foundation Trust, Umeå University, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique [Nancy] (CIC), University of Southampton, University of Oxford [Oxford], University of Sheffield [Sheffield], Université de Liège, Geneva University Hospitals and Geneva University, Hôpital Roger Salengro [Lille], Università degli studi di Palermo - University of Palermo, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], CHU Toulouse [Toulouse], CNR Institute of Neuroscience, University of Padova, University of Helsinki, University of Oulu, Department of Geriatrics - Efficiency and Deficiency Laboratory, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ), Service de médecine gériatrique, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Department of public health, Service of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva University Hospital and Geneva University, Service de rhumatologie[Lille], Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne ( UB ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Nottingham University Hospitals NHS Trust [UK], Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Department of Electrical Engineering and Automation [Aalto University], Aalto University (A?), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lorraine (UL), Centre Hospitalier Universitaire de Nancy (CHU Nancy), C.H.U. Sart Tilman [Liège], Charité-University Medical Center - UniversitätsMedizin [Berlin], Gérontopôle, CHU Toulouse [Toulouse]-Epidémiologie et Analyses en Santé Publique : risques, maladies chroniques et handicap (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Biomedical Sciences [Padova, Italy] (Neuroscience Institute), Italian National Research Council [Padova, Italy]-University of Padova [Padova, Italy], Helsinki University Central Hospital [Finland] (HUCH), Department of Ageing and Health, Guy's and St. Thomas' NHS Foundation Trust, Geneva University Hospital (HUG), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bourgogne (UB), Clinicum, Department of Medicine, Timo Strandberg / Principal Investigator, Geriatrian yksikkö, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CIC-Nancy, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Roger Salengro, Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), APH - Amsterdam Public Health, AMS - Amsterdam Movement Sciences, Geriatrics, Blain, H., Masud, T., Dargent-Molina, P., Martin, F.C., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., Kanis, J.A., Reginster, J.Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K.E., Vellas, B., Maggi, S., Strandberg, T., Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Herrada, Anthony, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Oxford, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Università degli Studi di Padova = University of Padua (Unipd), and Helsingin yliopisto = Helsingfors universitet = University of Helsinki
- Subjects
Gerontology ,Aging ,Statement (logic) ,Cost effectiveness ,Osteoporosis ,Poison control ,Medicine (miscellaneous) ,postmenopausal women ,Position statement ,Suicide prevention ,Occupational safety and health ,law.invention ,Fractures, Bone ,zoledronic acid ,0302 clinical medicine ,Randomized controlled trial ,Bone Density ,law ,Secondary Prevention ,Fall ,Nutrition and Dietetic ,Medicine ,030212 general & internal medicine ,risk-factors ,ComputingMilieux_MISCELLANEOUS ,media_common ,Geriatrics ,Aged, 80 and over ,Hip fracture ,Nutrition and Dietetics ,[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,osteoporotic fractures ,[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,Accidental Fall ,fall induced injuries ,Fragility fracture ,3. Good health ,Primary Prevention ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,randomized controlled-trials ,Fracture prevention ,bone-mineral density ,Falls ,Human ,medicine.drug ,medicine.medical_specialty ,education ,hip-fracture ,030209 endocrinology & metabolism ,[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,Article ,03 medical and health sciences ,pharmacological-treatments ,media_common.cataloged_instance ,Humans ,European Union ,European union ,cost-effectiveness ,Aged ,Postmenopausal women ,business.industry ,Public health ,Prevention ,Osteoporosi ,medicine.disease ,[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition ,Zoledronic acid ,3121 General medicine, internal medicine and other clinical medicine ,ddc:618.97 ,Physical therapy ,Accidental Falls ,fragility fracture ,older people ,position statement ,prevention ,Geriatrics and Gerontology ,Older people ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,Geriatric - Abstract
Published also in Aging Clinical and Experimental Research, Vol.28, No.4, WOS: 000379034800030 Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) - European society for clinical and economic aspects of osteoporosis and osteoarthritis (ECCEO), outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people. (C) 2016 Published by Elsevier Masson SAS.
- Published
- 2016
- Full Text
- View/download PDF
5. Within-run precision and outlier detection for the Abbott ARCHITECT cardiac troponin I assay. Authors' reply
- Author
-
N, Sawyer and S, Vasikaran
- Subjects
Male ,Troponin I ,Humans ,Female ,Blood Chemical Analysis - Published
- 2014
6. Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another
- Author
-
L.C. Ward, D.L. Faulkner, G.O. Stewart, Richard L. Prince, R.W. Retallack, Chotoo I. Bhagat, Elizabeth Geelhoed, S.K. Gan, Roger I. Price, A. Criddle, B.G.A. Stuckey, G.N. Kent, R.K. Will, S. Vasikaran, and D.H. Gutteridge
- Subjects
Male ,medicine.medical_specialty ,Deoxypyridinoline ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Drug Resistance ,Pamidronate ,Reference range ,Gastroenterology ,Excretion ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Orthopedics and Sports Medicine ,Prospective cohort study ,Aged ,Creatinine ,Alendronate ,Diphosphonates ,business.industry ,Alendronic acid ,Pamidronic acid ,Bisphosphonate ,Osteitis Deformans ,Endocrinology ,chemistry ,Female ,business ,medicine.drug - Abstract
Twenty-five years after the first paper on etidronate in Paget's disease, there are few published papers that address bisphosphonate resistance as a specific clinical phenomenon. We report our data from two studies. Study 1 is a retrospective study of 20 patients with moderate to severe disease who were treated with intravenous (iv) pamidronate (221 +/- 18 mg [SEM]; range 60-360 mg), and after biochemical remission and relapse were retreated with generally larger iv dosage (293 +/- 28 mg; range 180-600 mg). The nadir bone turnover values were similar: plasma alkaline phosphatase (pAP) in 20 patients was 243 +/- 40 IU/l (mean +/- SEM) after the first course, and 267 +/- 44 IU/l after the second (reference range [RR] 35-135 IU/l). Likewise, fasting urinary hydroxyproline excretion (HypE) in 14 of the 20 patients was 4.5 +/- 1.1 micromol/LGF and 4.1 +/- 0.9 micromol/LGF, respectively (RR 0.40-1.92 micromol/LGF). However the minimum duration of biochemical remission was significantly shorter after the second course-10.9 +/- 1.7 months (first) and 5.6 +/- 0.9 months (second) (p0.03; Friedman's ANOVA n = 17). A subgroup of 10 patients who were followed for three courses showed a significantly higher pAP nadir in the third course. Study 2 is a prospective study of 40 patients, 23 previously untreated (NILPREV) and 17 previously treated with iv pamidronate (PAMPREV) and in biochemical relapse, who were randomly allocated to either oral alendronate 40 mg daily in 3 month units, or iv pamidronate 60 mg every 3 months. Treatment was continued until pAP and fasting urinary deoxypyridinoline/creatinine (Dpy/Cr) ratios (RR 5-27 micromol/mol) were both in the reference range, or a clear plateau in each marker developed. At baseline, there were no significant differences in either marker between the two NILPREV groups and between the two PAMPREV groups. Using log-transformed data, in NILPREV the pAP reductions were significant and similar over the first 6 months. However, although each Dpy/Cr reduction was also significant, the difference in responses favored alendronate (p0.015). In PAMPREV both markers showed no significant response to pamidronate; comparison showed a significantly greater response to alendronate (pAP p0.02; Dpy/Cr p0.002). Using two-way ANOVA, the pAP responses to alendronate in NILPREV and PAMPREV were similar and those to pamidronate were different (p = 0.034). The percentage of patients with both markers in the RR at 6 months or earlier were identical in NILPREV patients: alendronate 87% and pamidronate 87%. However in PAMPREV they were different: alendronate 83% and pamidronate 0% (p = 0.003). These data indicate: 1) patients treated with the same aminobisphosphonates for two courses show similar nadir values of bone turnover markers but a shorter remission time after the second course. In a third course the nadirs are significantly higher; and 2) in the alendronate/pamidronate comparison, NILPREV and PAMPREV patients showed similar pAP responses to alendronate, but significantly different responses to pamidronate. Thus, patients showing acquired partial resistance to one aminobisphosphonate (usually after two or more previous courses) are still capable of remission after exposure to another compound of the same class.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.